In 2008, King’s College London, on behalf of the BRC, entered into a five-year strategic agreement with BD Biosciences, a part of BD (Becton, Dickinson and Company) to work together on the development of clinical diagnostics and research platforms for clinical applications in the field of immunology.
The collaboration enables us to innovate and advance translational research into the diagnosis and treatment of patients with a range of conditions including sepsis, infection, rheumatoid arthritis, inflammatory bowel diseases, transplant rejection, severe skin disease (psoriasis) and systemic lupus. This agreement was brokered by King’s Business.
The NIHR Biomedical Research Center (BRC) at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, a long-standing Mass Cytometry contributor, collaborator and partner, formalised a collaborative alliance with Fluidigm in 2015.
The Immune Monitoring Core of the BRC will collaborate and partner with Fluidigm to develop new applications, and as such, help to further broaden applications with Fluidigm’s Helios™ technology.
The partnership with Fluidigm allows the BRC to develop its cutting-edge research infrastructure and, as a Helios service provider, empowers researchers to use expanded applications in high resolution single-cell profiling and discovery, particularly in the fields of cancer biology, immunology and immuno-oncology.
The genomics facility on the 7th floor of Tower Wing, Guy’s Hospital, is a recognised Illumina site. It is equipped with state-of-the-art instrumentation providing a comprehensive range of applications allied to Illumina equipment and other platforms, for genomic sequencing, genotyping and gene expression studies.
For over three years, the Department of Twin Research & Genetic Epidemiology, King’s College London has successfully collaborated with Pfizer, Inc, one of the world’s leading pharmaceutical companies dedicated to the discovery and development of new medicines.
The research effort is focused on performing quantitative sensory testing in over 2000 healthy individuals and sequencing coding regions of candidate genes in over 200 individuals in the extreme ends of the pain response distribution in order to identify gene targets and novel pathways that may subsequently be amenable to pain therapeutics.
Novel techniques of methylation sequencing are also being used to assess differentially methylated regions in pain-insensitive and pain-sensitive twin pairs.